ELLIOTT P contact VICHINSKY

Summary

Affiliation: Children's Hospital and Research Center
Country: USA

Publications

  1. pmc Clinical manifestations of α-thalassemia
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Cold Spring Harb Perspect Med 3:a011742. 2013
  2. doi request reprint Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine
    Elliott Vichinsky
    Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Hematology Am Soc Hematol Educ Program 2012:271-5. 2012
  3. doi request reprint Advances in the treatment of alpha-thalassemia
    Elliott Vichinsky
    Children s Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA
    Blood Rev 26:S31-4. 2012
  4. ncbi request reprint Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group
    E P Vichinsky
    Department of Hematology Oncology, Children s Hospital Oakland, Calif 94609, USA
    N Engl J Med 342:1855-65. 2000
  5. ncbi request reprint Changes in the epidemiology of thalassemia in North America: a new minority disease
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center, Oakland, CA, USA
    Pediatrics 116:e818-25. 2005
  6. ncbi request reprint Clinical application of deferasirox: practical patient management
    Elliott Vichinsky
    Hematology Oncology Department, Children s Hospital and Research Center at Oakland, Oakland, California 94609, USA
    Am J Hematol 83:398-402. 2008
  7. doi request reprint Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial
    Elliott Vichinsky
    Children s Hospital and Research Center, Oakland, CA 94609, USA
    Acta Haematol 119:133-41. 2008
  8. pmc Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, 747 52nd St, Oakland, CA 94609, USA
    JAMA 303:1823-31. 2010
  9. ncbi request reprint Changing patterns of thalassemia worldwide
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:18-24. 2005
  10. doi request reprint Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey
    Elliott P Vichinsky
    Hematology Oncology Department, Children s Hospital and Research Center Oakland, CA 94609, USA
    Pediatr Hematol Oncol 28:37-42. 2011

Research Grants

  1. Modulation of Iron Deposition in SCD and Other Hemoglobinopathies
    Elliott Vichinsky; Fiscal Year: 2009
  2. THALASSEMIA CLINICAL RESEARCH NETWORK
    Elliott Vichinsky; Fiscal Year: 2007
  3. Eighth Cooley's Anemia Symposium
    Elliott Vichinsky; Fiscal Year: 2005
  4. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2004
  5. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2003
  6. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2002
  7. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2002
  8. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2001
  9. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2001
  10. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2000

Detail Information

Publications52

  1. pmc Clinical manifestations of α-thalassemia
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Cold Spring Harb Perspect Med 3:a011742. 2013
    ..Affected pregnancies result in severe fetal and maternal complications. Doppler ultrasonography with intrauterine transfusion therapy may improve the fetal prognosis but creates ethical challenges for the family and health providers...
  2. doi request reprint Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine
    Elliott Vichinsky
    Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Hematology Am Soc Hematol Educ Program 2012:271-5. 2012
    ..To evaluate these therapies optimally, recommendations for improving clinical trial design in hemoglobinopathies are discussed...
  3. doi request reprint Advances in the treatment of alpha-thalassemia
    Elliott Vichinsky
    Children s Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA
    Blood Rev 26:S31-4. 2012
    ..These patients often require comprehensive, multidisciplinary care. This chapter focuses on screening, diagnosis, and treatment approaches for patients with Hb H disease...
  4. ncbi request reprint Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group
    E P Vichinsky
    Department of Hematology Oncology, Children s Hospital Oakland, Calif 94609, USA
    N Engl J Med 342:1855-65. 2000
    ..Since its cause is largely unknown, therapy is supportive. Pilot studies with improved diagnostic techniques suggest that infection and fat embolism are underdiagnosed in patients with the syndrome...
  5. ncbi request reprint Changes in the epidemiology of thalassemia in North America: a new minority disease
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center, Oakland, CA, USA
    Pediatrics 116:e818-25. 2005
    ..Characterization of the new spectrum of this ancient disease, now predominated by minority groups, is essential for optimizing survival...
  6. ncbi request reprint Clinical application of deferasirox: practical patient management
    Elliott Vichinsky
    Hematology Oncology Department, Children s Hospital and Research Center at Oakland, Oakland, California 94609, USA
    Am J Hematol 83:398-402. 2008
    ..As with any new agent, it is important that treating physicians are familiar with the adverse event profile of deferasirox and how the associated effects can be readily managed to ensure optimal use of this important treatment...
  7. doi request reprint Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial
    Elliott Vichinsky
    Children s Hospital and Research Center, Oakland, CA 94609, USA
    Acta Haematol 119:133-41. 2008
    ..However, resultant iron overload can be life threatening if untreated. Chelation therapy with deferoxamine requires parenteral infusions that can negatively impact quality of life and adherence to treatment...
  8. pmc Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center Oakland, 747 52nd St, Oakland, CA 94609, USA
    JAMA 303:1823-31. 2010
    ..Sickle cell anemia (SCA) is a chronic illness causing progressive deterioration in quality of life. Brain dysfunction may be the most important and least studied problem affecting individuals with this disease...
  9. ncbi request reprint Changing patterns of thalassemia worldwide
    Elliott P Vichinsky
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:18-24. 2005
    ..Comprehensive services that address language and social barriers as well as access to Hb F-enhancing agents and transfusions are needed...
  10. doi request reprint Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey
    Elliott P Vichinsky
    Hematology Oncology Department, Children s Hospital and Research Center Oakland, CA 94609, USA
    Pediatr Hematol Oncol 28:37-42. 2011
    ..As evidence suggests more patients with SCD could benefit from regular transfusion therapy, it is apparent that greater awareness of the need to monitor and treat iron overload in transfused patients is required...
  11. doi request reprint Transfusion and chelation practices in sickle cell disease: a regional perspective
    Elliott P Vichinsky
    Hematology Oncology Department, Children s Hospital and Research Center Oakland, California 94609, USA
    Pediatr Hematol Oncol 28:124-33. 2011
    ....
  12. pmc Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
    Elliott Vichinsky
    Children s Hospital and Research Center at Oakland, Oakland, CA 94609, USA
    Br J Haematol 154:387-97. 2011
    ..Iron burden was substantially reduced with appropriate dosing in patients treated for at least 4 years...
  13. doi request reprint Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy
    Elliott Vichinsky
    Children s Hospital and Research Center Oakland, Oakland, Califorina, USA
    Ann N Y Acad Sci 1202:180-7. 2010
    ..Universal newborn screening has been adopted in several regions with DNA confirmatory testing. These advances have resulted in ethical dilemmas for the family and the provider...
  14. ncbi request reprint New therapies in sickle cell disease
    Elliott Vichinsky
    Department of Hematology Oncology, Children s Hospital Oakland, Oakland, CA 94609, USA
    Lancet 360:629-31. 2002
    ..NO regulates blood vessel tone, endothelial adhesion, and the severity of ischaemia-reperfusion injury and anaemia in SCD. Although NO is difficult to administer, its precursor, L-arginine, is an oral supplement...
  15. doi request reprint Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia
    Elliott Vichinsky
    Children s Hospital and Research Center, Hematology Oncology Department, 747 52nd St, Oakland, CA 94609, USA
    Pediatrics 121:1253-6. 2008
  16. ncbi request reprint Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial
    E P Vichinsky
    Department of Hematology Oncology, Children s Hospital Oakland, Oakland, California 94609, USA
    Transfusion 41:1086-92. 2001
    ..The purpose of this study was to determine if a multicenter trial could implement a transfusion program utilizing phenotypically matched blood to reduce alloimmunization...
  17. pmc A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
    Elliott Vichinsky
    Children s Hospital and Research Center, Oakland, CA 94609, USA
    Br J Haematol 136:501-8. 2007
    ..Once-daily oral deferasirox has acceptable tolerability and appears to have similar efficacy to deferoxamine in reducing iron burden in transfused patients with sickle cell disease...
  18. pmc Relationship between chronic transfusion therapy and body composition in subjects with thalassemia
    Ellen B Fung
    Department of Hematology, Children s Hospital and Research Center, Oakland, CA, USA
    J Pediatr 157:641-7, 647.e1-2. 2010
    ..To measure body composition in patients with thalassemia and explore its relationship to abnormal growth and bone mass...
  19. pmc Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center at Oakland, CA 94609, USA
    JAMA 294:81-90. 2005
    ..We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes...
  20. pmc Hemolysis-associated pulmonary hypertension in thalassemia
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center at Oakland, 747 52nd Street, Oakland, California 94609, USA
    Ann N Y Acad Sci 1054:481-5. 2005
    ..Erythrocyte release of arginase during hemolysis contributes to the development of PHT. Therapies that maximize arginine and nitric oxide bioavailability may benefit patients with thalassemia...
  21. ncbi request reprint Treatment of hepatitis C virus infection in thalassemia
    Ellen Butensky
    Department of Gastroenterology and Nutrition, Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:290-9. 2005
    ..Although transfusion requirements increased in most patients, iron burden was not necessarily increased...
  22. ncbi request reprint Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression
    Zandra A Jenkins
    Council for BioIron at CHORI, Children s Hospital Oakland Research Institute, Oakland, California 94609, USA
    Pediatr Hematol Oncol 24:237-43. 2007
    ..Finally, the absence of a detectable change in ferritin mRNA indicates insufficient oxidative stress to significantly activate MARE/ARE promoters...
  23. ncbi request reprint Outcomes of preimplantation genetic diagnosis therapy in treatment of beta-thalassemia: A retrospective analysis
    Naveen Qureshi
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, 747 52nd St, 2nd Floor, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:500-3. 2005
    ..Improvements in PGD therapy's efficacy and cost will make this a more viable option for affected families...
  24. ncbi request reprint Clinical differences between children and adults with pulmonary hypertension and sickle cell disease
    R Ward Hagar
    Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    Br J Haematol 140:104-12. 2008
    ..3 (95% confidence interval 4.9-60.4). The divergent clinical spectrum for PHT between adults and children may point to different age-specific mechanisms or biological expression of PHT...
  25. ncbi request reprint Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome
    Sylvia T Singer
    Children s Hospital and Research Center at Oakland, CA 94609, USA
    Br J Haematol 131:378-88. 2005
    ..Continuous monitoring of toxicity and growth is required...
  26. ncbi request reprint Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center at Oakland, Oakland, California 94609, USA
    J Pediatr Hematol Oncol 25:629-34. 2003
    ..The authors have previously shown that Arg supplementation alone induces a paradoxical decrease in NO metabolite (NO(x)) production...
  27. pmc Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia
    Ellen B Fung
    Department of Hematology at the Children s Hospital and Research Center, Oakland, CA, USA
    Bone 43:162-8. 2008
    ..Though ethnic differences in fracture risk cannot be ignored, endocrinopathy is rare in TxSCD which may also provide some protection from fracture...
  28. doi request reprint Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions
    Ellen B Fung
    Department of Hematology, The Children s Hospital and Research Center, Oakland, California, USA
    Transfusion 48:1971-80. 2008
    ..The objective of this study was to evaluate the current standard of care in monitoring iron overload and related complications in patients with SCD compared to thalassemia (Thal)...
  29. ncbi request reprint Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital Oakland, 747 52nd Street, Oakland, CA 94609, USA
    Am J Respir Crit Care Med 168:63-9. 2003
    ..With limited treatment options and a high mortality rate for patients with sickle cell disease who develop pulmonary hypertension, arginine is a promising new therapy that warrants further investigation...
  30. ncbi request reprint Bone mineral density in children with sickle cell anemia
    Ashutosh Lal
    Children s Hospital and Research Center at Oakland, Oakland, California 94609, USA
    Pediatr Blood Cancer 47:901-6. 2006
    ..We evaluated bone mineral density (BMD) and risk factors for poor bone mineralization in children with sickle cell anemia (SCA)...
  31. ncbi request reprint Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment
    Lynne D Neumayr
    Department of Hematology, Children s Hospital and Research Center, 747 52nd Street, Oakland, CA 94609, and Department of Orthopaedic Surgery, University of California, San Francisco 94143, USA
    J Bone Joint Surg Am 88:2573-82. 2006
    ..However, the efficacy of hip core decompression to prevent the progression of osteonecrosis in these patients is still controversial...
  32. doi request reprint Heterogeneity of hemoglobin H disease in childhood
    Ashutosh Lal
    Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
    N Engl J Med 364:710-8. 2011
    ..Early diagnosis during newborn screening or infancy has enabled the observation of the natural history of hemoglobin H disease, a subtype of α-thalassemia...
  33. ncbi request reprint Diseases of iron metabolism
    Ward Hagar
    Department of Hematology Oncology, Oakland Children s Hospital, CA 94609, USA
    Pediatr Clin North Am 49:893-909. 2002
    ..Review of the blood indices and serum iron and ferritin markers may alert the clinician to most disorders. Further research is likely to define the scope and approach to clinical diagnosis of the diseases of iron metabolism...
  34. ncbi request reprint Quality of life in patients with thalassemia intermedia compared to thalassemia major
    Zahra Pakbaz
    Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:457-61. 2005
    ..Presented data suggest that all patients with thalassemia undergo QOL assessment so that interventions focused on affected domains can be implemented...
  35. ncbi request reprint Utility of Holter electrocardiogram in iron-overloaded hemoglobinopathies
    Naveen Qureshi
    Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, 747 52nd Street, 2nd Floor, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:476-80. 2005
    ..Other screening modalities, including the transtelephonic event recorder, should be evaluated in arrhythmia surveillance...
  36. ncbi request reprint Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment
    Sylvia T Singer
    Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:250-6. 2005
    ..After 5 years of follow-up, a subset of patients remained off transfusions. Hydroxyurea should be considered for a subset of Hb E-beta 0-thalassemia patients...
  37. ncbi request reprint A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia
    Zahra Pakbaz
    Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:486-91. 2005
    ..Education and frequent noninvasive LIC assessments can improve adherence and iron burden. Elevated LIC does not necessarily reflect concurrent noncompliance; however, it can be an indication of nonadherence in the past...
  38. ncbi request reprint Liver ferritin subunit ratios in neonatal hemochromatosis
    Ward Hagar
    Children s Hospital, Oakland, Research Institute, Oakland, California 95609, USA
    Pediatr Hematol Oncol 20:229-35. 2003
    ..This first report of a marked increase in the ferritin H/L-subunit ratio may point to an underlying mechanism of disease in this enigmatic disorder...
  39. ncbi request reprint Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state
    Sylvia T Singer
    Children s Hospital and Research Center at Oakland, Hematology Oncology Department, Oakland, CA 94609 1808, USA
    Am J Hematol 81:670-5. 2006
    ..This study underscores the role of platelet activation in the development of PAH and stresses its occurrence even among patients who are regularly transfused, especially those who are older and have had splenectomies...
  40. ncbi request reprint Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease
    Ellen B Fung
    Department of Hematology, Children s Hospital and Research Centre, Oakland, CA, USA
    Br J Haematol 135:574-82. 2006
    ..However, because transfusion duration remained a significant predictor of endocrinopathy, these data should be confirmed in SCD subjects that have been chronically transfused for longer periods of time...
  41. pmc Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells
    Sylvia T Singer
    Hematology Oncology Department and Clinical Research Center at Oakland, CA, USA
    Am J Hematol 83:842-5. 2008
    ..These findings underscore the disappointing results of hydroxyurea treatment in clinical trials and the importance of examining the effect on RBC characteristics for the development and understanding of HbF-enhancing agents...
  42. ncbi request reprint Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale--a modification of the Harris Hip Score
    Christine M Aguilar
    Division of Padiatric Rehabilitation, Children s Hospital and Research Center, Oakland, CA 94609, USA
    Arch Phys Med Rehabil 86:1369-75. 2005
    ..To establish the validity and reliability of the Children's Hospital Oakland Hip Evaluation Scale (CHOHES), a modification of the Harris Hip Score, for the evaluation of avascular necrosis (AVN) in sickle cell disease (SCD)...
  43. doi request reprint Pulmonary hypertension in thalassemia
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center Oakland, Oakland, California, USA
    Ann N Y Acad Sci 1202:205-13. 2010
    ..Guidelines for the management of PH in thalassemia have not yet been established; however, clinical trials are ongoing in an effort to guide future therapy...
  44. ncbi request reprint Measuring chromosome breaks in patients with thalassemia
    Tal Offer
    Children s Hospital Oakland Research Institute, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:439-44. 2005
    ..Our findings indicate that higher levels of micronuclei frequencies are present in thalassemic RBCs...
  45. pmc Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center Oakland, 747 52nd St, Oakland, CA 94609, USA
    Blood 111:402-10. 2008
    ..Decreased erythrocyte glutathione and glutamine levels contribute to alterations in the erythrocyte redox environment, which may compromise erythrocyte integrity, contribute to hemolysis, and play a role in the pathogenesis of PH of SCD...
  46. ncbi request reprint Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease
    Charles H Pegelow
    Department of Pediatrics, University of Miami, Miami, FL 33101, USA
    Blood 99:3014-8. 2002
    ..Until safe and effective preventive strategies against infarct recurrence are discovered, MRI studies are best reserved for children with neurologic symptoms, neuropsychometric deficits, or elevated cerebral artery velocities...
  47. ncbi request reprint Hemoglobin E-beta-thalassemia: Progress report from the International Study Group
    Anuja Premawardhena
    Department of Medicine, University of Kelaniya, Kelaniya, Sri Lanka
    Ann N Y Acad Sci 1054:33-9. 2005
    ..These preliminary observations, made over the last 7 years, provide directions for future research into this increasingly important disease...
  48. ncbi request reprint Pulmonary hypertension in sickle cell disease
    Elliott P Vichinsky
    Department of Hematology Oncology, Northern California Sickle Cell Center, Children s Hospital and Research Center at Oakland, USA
    N Engl J Med 350:857-9. 2004
  49. pmc Managing sickle cell disease
    Susan Claster
    University of California at San Francisco, San Francisco General Hospital, 995 Portrero Avenue, Building 80, Ward 84, Box 0874, San Francisco, CA 94110, USA
    BMJ 327:1151-5. 2003
  50. ncbi request reprint Dose-escalation study of ICA-17043 in patients with sickle cell disease
    Kenneth I Ataga
    Division of Hematology Oncology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Pharmacotherapy 26:1557-64. 2006
    ..To determine the dose tolerance, safety, and pharmacokinetics of a single oral dose of ICA-17043 in patients with sickle cell disease...
  51. ncbi request reprint Deferiprone and hepatic fibrosis
    Gary M Brittenham
    Blood 101:5089-90; author reply 5090-1. 2003
  52. ncbi request reprint Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study
    Winfred C Wang
    Hematology Division, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Pediatr 140:225-9. 2002
    ..We report the growth characteristics of patients in the Phase I-II pediatric hydroxyurea trial (HUG-KIDS) before and during treatment at the maximum tolerated dose for one year...

Research Grants15

  1. Modulation of Iron Deposition in SCD and Other Hemoglobinopathies
    Elliott Vichinsky; Fiscal Year: 2009
    ....
  2. THALASSEMIA CLINICAL RESEARCH NETWORK
    Elliott Vichinsky; Fiscal Year: 2007
    ....
  3. Eighth Cooley's Anemia Symposium
    Elliott Vichinsky; Fiscal Year: 2005
    ....
  4. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2004
    ....
  5. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2003
    ....
  6. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2002
    ..In summary, if this study is successful, it will change the approach to Hb E/B worldwide and result in improved quality of life and decreased mortality. (End of Abstract) ..
  7. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2002
    ....
  8. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2001
    ..In summary, if this study is successful, it will change the approach to Hb E/B worldwide and result in improved quality of life and decreased mortality. (End of Abstract) ..
  9. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2001
    ....
  10. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2000
    ..In summary, if this study is successful, it will change the approach to Hb E/B worldwide and result in improved quality of life and decreased mortality. (End of Abstract) ..
  11. SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD
    Elliott Vichinsky; Fiscal Year: 2000
    ....
  12. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 1999
    ..In summary, if this study is successful, it will change the approach to Hb E/B worldwide and result in improved quality of life and decreased mortality. (End of Abstract) ..
  13. Modulation of Iron Deposition in SCD and Other Hemoglobinopathies
    ELLIOTT P contact VICHINSKY; Fiscal Year: 2010
    ....